Antihypertensive Therapy

Blood Pressure Lowering Effects of Pharmacological and Device Based Interventions for Resistant Hypertension: A Systematic Review and Meta-Analysis

by Prateek Chopra | June 17, 2026 | Cardiology Conferences | ESH 2026 Clinical Context: Resistant hypertension (RHTN) remains a major clinical challenge. This systematic review and meta-analysis evaluated the blood pressure-lowering efficacy and hypertension control rates achieved after the addition of pharmacological or device-based interventions (e.g., renal denervation, RDN) in patients with true RHTN. Study Design: Key Findings: Clinical Implications: […]

Blood Pressure Lowering Effects of Pharmacological and Device Based Interventions for Resistant Hypertension: A Systematic Review and Meta-Analysis Read Post »

Leave a Comment / ESH Day 4 / bluetree.healthcare@gmail.com / July 29, 2026 / Antihypertensive Therapy, Blood Pressure Control, Renal Denervation (RDN), Resistant Hypertension, Systematic Review and Meta-Analysis

Efficacy and Safety of Initial Low-Dose Triple CombinationTherapy for Hypertension: A Systematic Review and Meta-Analysis

by Prateek Chopra | June 10, 2026 | Cardiology Conferences | ESH 2026 Context and Rationale: Single-pill triple low-dose combination (triple-LDC) antihypertensive therapies have emerged as an alternative initial treatment strategy, expanding options beyond conventional monotherapy. The therapy aims to improve BP control while minimizing adverse effects by using ≤50% of standard doses for each component. Study Design: Trial Population and

Efficacy and Safety of Initial Low-Dose Triple CombinationTherapy for Hypertension: A Systematic Review and Meta-Analysis Read Post »

Leave a Comment / ESH Day 2 / bluetree.healthcare@gmail.com / July 29, 2026 / Antihypertensive Therapy, Blood Pressure Control, Hypertension Management, Single-Pill Combination Therapy (SPC), Triple Low-Dose Combination Therapy

Effects of a New Low-Dose Triple Single-Pill Antihypertensive Combination on Electrolytes and Creatinine Compared to Placebo and Dual Therapies

by Prateek Chopra | June 9, 2026 | Cardiology Conferences | ESH 2026 Therapeutic Context: Triple SPCs containing three low-dose antihypertensive agents are emerging as a promising strategy for improving BP control. GMRx2 (telmisartan/amlodipine/indapamide; WIDAPLIK) was recently FDA-approved, and its effects on serum electrolytes and renal function were evaluated against placebo and dual-combination therapies. Study Design: Placebo-Controlled Trial Findings: Active-Controlled Trial

Effects of a New Low-Dose Triple Single-Pill Antihypertensive Combination on Electrolytes and Creatinine Compared to Placebo and Dual Therapies Read Post »

Leave a Comment / ESH Day 2 / bluetree.healthcare@gmail.com / July 29, 2026 / Antihypertensive Therapy, Blood Pressure Control, GMRx2 (WIDAPLIK), Hypertension Management

Triple SPCs: Simplifying Treatment, Strengthening Control

by Prateek Chopra | June 8, 2026 | Cardiology Conferences | ESH 2026 Simplifying Hypertension Care: Despite hypertension being a leading contributor to cardiovascular morbidity and mortality, BP control remains suboptimal due to poor adherence, therapeutic inertia, and complex multi-drug regimens. Triple single-pill combinations (SPCs) simplify therapy, improve adherence, accelerate BP target attainment, and enhance long-term cardiovascular outcomes. Guideline-Based Recommendations: Real-World

Triple SPCs: Simplifying Treatment, Strengthening Control Read Post »

Leave a Comment / ESH Day 2 / bluetree.healthcare@gmail.com / July 29, 2026 / Antihypertensive Therapy, Blood Pressure Control, Cardiovascular Disease Prevention, Hypertension Management, Single-Pill Combination Therapy (SPC)